Indegene (INDGN) Q1 25/26 earnings summary

Executive summary

• Q1 FY2026 revenue reached INR 7,608 million, up 12.5% year-over-year and 0.7% sequentially, with strong performance in enterprise segments and new strategic initiatives like Tectonic and Runway11 gaining traction.

• EBITDA stood at INR 1,536 million, with a stable margin of 20.2%; PAT was INR 1,164 million, up 32.7% year-over-year and 2.3 pts YoY, but down 1% sequentially.

• Board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, with auditor's unmodified opinion.

• Strategic priorities for FY2026 include expanding AI-enabled solutions, strengthening sales and consulting leadership, and pursuing M&A opportunities.

• Focused on deeper engagement with large pharma clients and broader targeting to expand the client base.

Financial highlights

• Revenue from operations reached INR 7,608 million, up 12.5% year-over-year and 0.7% quarter-on-quarter.

• EBITDA margin was stable at 20.2%; PAT margin at 15.3%, down 0.3 pts sequentially and up 2.3 pts YoY.

• PBT rose 27.1% year-over-year and 1.9% quarter-on-quarter.

• Cash and cash equivalents reached INR 17,280 million, exceeding $200 million.

• Basic EPS (consolidated) for Q1 FY26 was ₹4.86, up from ₹3.79 in Q1 FY25.

Outlook and guidance

• Deal pipeline has improved, with new large deals and advanced conversations in progress.

• Management expects continued growth in enterprise segments and sees medium-term margin expansion as a possibility, while near-term margins are expected to remain around 20% EBITDA.

• Strategic focus areas identified for FY26 to support medium and long-term growth, with continued investment in scaling transformative engagements and M&A opportunities.

• No explicit forward-looking guidance provided, but segment and revenue growth trends indicate continued momentum.

• AI and digital transformation are expected to drive differentiation and market share gains.